About the study 

Thank you to everyone who participated. Analysis of the data that was shared with us is now complete and the study is going through the final stages of sign out before publication. Information on where you can read the results will be provided here when available.

International data suggests that for most people who develop myocarditis and/or pericarditis, their symptoms stop with appropriate management. However, there is limited data on the long-term health outcomes of individuals who experience these reactions.  

This study was a collaborative effort across the Ministry of Health, Medsafe, and Centre for Adverse Reactions Monitoring (CARM) to help us to better understand how the Pfizer COVID-19 vaccine is working in Aotearoa New Zealand.

About myocarditis and pericarditis 

Who could participate


  • Were aged 12 or over 
  • Were diagnosed with myocarditis and/or pericarditis following any dose of the Pfizer COVID-19 vaccine (up to and including 28 February 2022) 
  • Had a report submitted to the Centre for Adverse Reactions Monitoring (CARM).

Submit a report to CARM 

Anyone who experienced myocarditis or pericarditis after their COVID-19 vaccine and has not yet reported this can submit a CARM report at any time. You can also discuss this with your health care provider, or call the COVID Healthline 0800 358 5453.

Submit a CARM report online 

What the study involves 

The survey was carried out over the phone by trained nurse interviewers from Reach Aotearoa (formerly CBG Health Research) – a New Zealand company experienced in carrying out health surveys.  

Other options, such as face-to-face or virtual interviews, were available depending on preference.  

During the survey, we asked permission to contact the healthcare professional who treated the participant. This was so we could ask for information about medications prescribed and test results to get a better understanding of the participants health following myocarditis and/or pericarditis.  

Results of the study

Results are expected to be published online in 2024. Information on where you can read the results will be provided here when available.


Information given to the interviewer is protected by the Privacy Act 2020. Information is grouped and an individual's information cannot be traced and will always remain confidential.

In the future, health researchers may want to contact participants about follow-up research on health, or health services, relating to myocarditis and pericarditis. We will only invite people to take part in follow-up research if they consent for this at the end of the interview. People invited to take part in any future studies can refuse if they do not want to take part.

More information